Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04993066 · ClinicalTrials.gov registry record · NA
Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus
A NA study, sponsored by Candela Corporation.
- Completed
- Registry status
- NA
- Development phase
- 77
- Enrollment target
NCT04993066: Completed NA study, sponsored by Candela Corporation.
NCT04993066 is a NA study that has completed, run by Candela Corporation. The registered enrollment target is 77 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04993066, a NA study, has completed, sponsored by Candela Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
Study Summary
Demonstrate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended uses: hair removal including pseudofolliculitis barbae (PFB), clearance of pigmented and/or vascular lesions, temporary increase of clear nail in patients with onychomycosis and improvement in appearance of wrinkles. Evaluate GentleMax Pro Plus™ laser system for the clearance of acne.
Primary Outcome
Evaluate the speed (time of treatment completion) with larger spot sizes for hair removal
Interventions
- DEVICE GentleMax Pro Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2023-04-27 |
| Phase | NA |
What the finished NCT04993066 record still lists
NCT04993066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which GentleMax Pro Plus is the first listed.
NCT04993066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04993066 about?
NCT04993066 is a clinical study titled "Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus". Demonstrate the safety and efficacy of the GentleMax Pro Plus™ laser system for its intended uses: hair removal including pseudofolliculitis barbae (PFB), clearance of pigmented and/or vascular lesions, temporary increase of clear nail in patients with onychomycosis and improvement in appearance of ...
What is the current status of trial NCT04993066?
This trial is currently completed. It is a NA study. The enrollment target is 77 participants. The study started on 2020-11-12. Estimated completion is 2023-04-27.
What interventions are being tested in trial NCT04993066?
The interventions under investigation include: GentleMax Pro Plus (DEVICE).
Who is sponsoring clinical trial NCT04993066?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04993066's enrollment target sits among peer trials
77 1062nd of 2000 higher than 939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI